Drug Profile
Research programme: cardiovascular and metabolic disorder therapeutics - Zealand Pharma
Alternative Names: GLP-1/GLP-2 dual agonist - Zealand Pharma; glucagon/GLP-1 agonists; ZP GG 72Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Developer Boehringer Ingelheim; Zealand Pharma
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; Glucagon-like peptide 2 receptor agonists; Islet amyloid polypeptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Metabolic disorders; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Obesity in Denmark (SC)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Obesity in Germany (SC)
- 20 Mar 2020 Boehringer Ingelheim returns the worldwide licence for amylin analogue to Zealand Pharma